[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Woman's\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100615070","phase-4-using-a-steroid-mouthwash-to-prevent-mouth-sores-during-chemotherapy-100615070",false,"NCT07287826","Using a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy","Study for Dexamethasone Mouthwash in Lowering Episodes of Oral Mucositis Among Patients With Cancer: The SMILE Study","SMILE","Inclusion criteria:\n\n* ≥18 years old\n* Confirmed cancer diagnosis\n* Scheduled to receive or receiving chemotherapy known to be associated with oral mucositis (e.g., anthracyclines and taxanes)\n* Ability to provide informed consent\n* Ability to comply with study procedures\n\nExclusion criteria:\n\n* Current tobacco usage or usage within the past 6 weeks.\n* HIV\u002FAIDS\n* Gastrointestinal disorder (such as Crohn's disease, ulcerative colitis, or celiac disease)\n* History of cold sores (herpes simplex virus)\n* Herpes zoster (oral shingles) within the past 6 weeks\n* Active oral infections at the time of enrollment (e.g., candidiasis)\n* Known sensitivity or allergy to dexamethasone\n* Inability to self-administer or tolerate mouthwash protocol\n* Concurrent enrollment in conflicting clinical trials\n* Existing oral ulcers or oral mucositis at enrollment\n* Pregnant\n* Uncontrolled diabetes mellitus as defined by HbA1c unknown or \\>8% in the past 3 months despite adequate therapy","ALL","18 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if a steroid mouthwash (dexamethasone) can prevent mouth sores caused by chemotherapy in adults with cancer. The main questions it aims to answer are:\n\nDoes using dexamethasone mouthwash before and during chemotherapy lower the chance of getting moderate to severe mouth sores?\n\nCan this approach reduce pain and improve comfort during chemotherapy?\n\nResearchers will compare patients using the mouthwash to a historical group of patients who received similar chemotherapy but did not use the mouthwash, to see if the mouthwash helps prevent mouth sores.\n\nParticipants will:\n\nUse a steroid mouthwash (4 times daily) for up to 8 weeks during chemotherapy\n\nComplete a short weekly survey about mouth discomfort during infusion visits",[27],"Oral Mucositis Due to Chemotherapy",[29],"oral mucositis","RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":34},"2026-04-02",{"date":38,"type":21},"2028-01",{"name":40,"class":41},"Woman's","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100429513","phase-4-treatment-to-regress-to-normoglycemia-in-women-with-a-recent-history-of-gdm-100429513","NCT04873050","Treatment to Regress to Normoglycemia in Women with a Recent History of GDM","A Randomized, Placebo-controlled, Double Blind Trial of Semaglutide 1mg (Ozempic®) on Regression to Normoglycemia in WomEn with a Recent History of Gestational DiabETes Mellitus: the SWEET Study","SWEET","Inclusion Criteria:\n\n1. Female\n2. 18 - 45 years old (inclusive)\n3. History of gestational diabetes in most recent pregnancy\n4. 6 months - 10 years postpartum\n5. BMI ≥ 25 kg\u002Fm2\n6. Use of long-acting reversible contraception or bilateral tubal ligation\n7. Dysglycemia as determined by glycemic response to 75g, 2-hour OGTT: either impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG\u002FIGT):\n\n   1. Fasting glucose 100-125mg\u002FdL (inclusive) and\u002For\n   2. 120 minute glucose 140-199mg\u002FdL (inclusive)\n8. Willingness to maintain physical activity level throughout study duration\n9. Willingness to standardize diet for 3 days prior to OGTT\n10. Ability to provide informed consent before any trial-related activities\n\nExclusion Criteria:\n\n1. Body weight \\> 350lb\n2. Pregnant or the intention of becoming pregnant or not using adequate contraceptive measures.\n3. Breastfeeding within 3 months of screening visit 1\n4. Post-menopausal\n5. Desiring pregnancy within study participation period or two months after participation ends (i.e. 10 months from enrolment)\n6. Use of tobacco products within past 6 months\n7. Substance or alcohol abuse\n8. Presence of significant systemic disease including: diabetes mellitus (type 1 or type 2), cardiac disease (e.g. congestive heart failure), renal impairment (e.g. serum creatinine levels ≥ 1.4 mg\u002FdL or eGFR \\\u003C 60), hepatic disease (including viral hepatitis, toxic hepatic damage, jaundice of unknown aetiology, or abnormal liver function tests), pancreatitis, uncontrolled thyroid disease (e.g. documented abnormal TSH), adrenal disease (including Cushing's syndrome, congenital adrenal hyperplasia), hyperlipidemia (fasting triglycerides \\> 399mg%), untreated or poorly controlled hypertension (resting blood pressure \\>159\u002F94 mmHg)\n9. History of or presence of: eating disorder, malignant disease requiring chemotherapy, or debilitating psychiatric disorder such as psychosis or neurological condition that could confound outcome variables\n10. History of bariatric surgery\n11. Use of medications for glucose regulation: insulin (e.g. Humalog, Novolog, Humulin), pramlintide, metiglinides, metformin, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors within four weeks of screening visit 1\n12. Use of medications for anti-obesity or weight loss within four weeks of screening visit 1\n13. Use of medications known to exacerbate glucose dysfunction (such as isotretinoin or corticosteroids) within four weeks of screening visit 1\n14. Known or suspected allergy to trial medication, excipients, or related products\n15. Contraindications to study medications: patients with a personal or family history of medullary thyroid cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)\n16. Current or recent past (within 3 months) participation in another experimental drug trial\n17. Previous randomization in this trial\n18. Receipt of any investigational drug within 6 months prior to this trial",true,"FEMALE","45 Years",{"count":55,"type":21},102,[24],"The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabetes recovery and reduce future risk of T2DM in young women.",[59,60],"Pre Diabetes","Postpartum Disorder","2025-03-10",{"date":63,"type":34},"2025-03-13",{"date":65,"type":34},"2022-01-13",{"date":67,"type":21},"2026-03-01",{"name":40,"class":41},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":51,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":87,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":42},"100366175","phase-4-latency-antibiotics-in-previable-pprom-18-07--22-67-wga-100366175","NCT04047849","Latency Antibiotics in Previable PPROM, 18 0\u002F7- 22 6\u002F7 WGA","The Effect of Antibiotics on Latency in Previable Prelabor Rupture of Membranes Between 18 0\u002F7 and 22 6\u002F7 Weeks Gestational Age","Inclusion Criteria:\n\n1. Singleton gestation\n2. Gestational age of greater than 18 0\u002F7 but less than or equal to 22 6\u002F7\n3. Diagnosis of prelabor premature rupture of membranes as determined by clinical examination noting either\u002For 1) visualization of amniotic fluid passing from the cervical canal and pooling in the vagina via sterile speculum examination, 2) a basic pH (i.e., positive nitrazine) test of vaginal fluid, 3) arborization (ferning) of dried vaginal fluid identified via microscopic examination, or 4) an amniotic fluid index (AFI) of less than 4cm\n4. Greater than or equal to 18 years of age\n5. Those with no known drug allergies or significant adverse reactions to azithromycin or amoxicillin\n6. Afebrile at the time of presentation and throughout 24-hour observation period\n7. Patient must be able to provide informed consent\n\nExclusion Criteria:\n\n1. Fetal anomalies in current pregnancy\n2. Diabetes mellitus, including both pre-gestational and gestational\n3. Abnormal placentation\n4. Poor dating with dating ultrasound performed later than or equal to 20 0\u002F7 weeks\n5. Current subchorionic hemorrhage or current vaginal bleeding on presentation\n6. Hypertensive disease, including pre-gestational chronic hypertension, gestational hypertension and pre-eclampsia\u002Feclampsia\n7. History of amniocentesis during this pregnancy\n8. History of cervical incompetence, history of cerclage in previous pregnancy or current cerclage in place\n9. Current documented urinary tract infection or bacteriuria\n10. Current documented genital tract infection (Chlamydia, gonorrhea, or trichomonas)\n11. Immunocompromised (i.e., HIV positive, daily steroid use, or a history of autoimmune disease for which the patient is currently undergoing treatment with immunotherapy medication)",{"count":77,"type":21},34,[24],"This study is a non-blinded, prospective, randomized controlled trial designed to compare the effect of outpatient oral antibiotics (i.e., amoxicillin and azithromycin) on the length of time (days) that pregnancy continues after a patient's water bag has ruptured prematurely. If a patient has been diagnosed with rupture of their water bag between 18 0\u002F7 weeks and 22 6\u002F7 weeks and there are no other associated complications with the pregnancy, the patient is eligible for initial consideration for this study. Patients will be admitted to the hospital for a 24-hour monitoring period. If the patient remains without further complications during this monitoring period, the patient will be eligible for enrollment. If enrollment is desired, the patient will be randomly assigned to receive either antibiotics (treatment arm of the study) or no antibiotics (control arm of the study). The treatment arm will receive an outpatient, 7-day course of oral antibiotics (azithromycin and amoxicillin) with the first dose given in the hospital to ensure no side effects. The control arm will not receive outpatient antibiotics. Both groups will have weekly, office follow-up visits with high-risk pregnancy specialists to ensure no further complications. Both groups will be admitted to the hospital if the patients reach 23 0\u002F7 weeks without complications. At this time the patients will receive all medications and therapies recommended by the governing board of OBGYNs. Subjects of both groups will also be admitted before 23 0\u002F7 weeks if further complications noted either at their clinic follow up visits or anytime outside of the hospital. The duration of time that the patient remains pregnant after breaking of the water bag will be compared in each group. The investigators will also see if there is a difference in the number of patients able to reach 23 0\u002F7 weeks between each group (treatment versus control).",[81,82,83,84,85,86],"Rupture of Membranes; Delayed Delivery (Following Spontaneous Rupture)","Rupture of Membranes; Premature","Rupture of Membranes; Premature, Affecting Fetus","Preterm Birth","Preterm PROM (Pregnancy)","Preterm Labor",[88,89,90,91,92,93],"Previable","PPROM","Premature prelabor rupture of membranes","Preterm","Preterm birth","Latency antibiotics","2021-01-07",{"date":96,"type":34},"2021-01-11",{"date":98,"type":34},"2019-08-28",{"date":100,"type":21},"2021-07-01",{"name":40,"class":41},""]